Pearl Huang has been active in the pharmaceutical industry for over 24 years, working primarily in the area of oncology drug discovery and development. She received her S.B. in Biology from MIT and a PhD in Molecular Biology from Princeton University, and has played multiple roles in basic discovery and clinical development in multiple big pharma organizations. Dr. Huang was also a founder of Beigene, a biotech in Asia. Currently, Dr. Huang is the global head of Discovery Partnerships in Academia (DPAc), where she is responsible for building a pipeline of medicines with academic partners, in all therapeutic areas and geographic locations. In addition to a building a core pipeline of candidate medicines, DPAc activities include the Discovery Fast Track Challenge and the Avalon/GSK alliance.
